Web Exclusives

Navigating through the oncology landscape has become increasingly challenging. As a result, it is imperative for oncology practices today to stay abreast of the changes occurring in the field to succeed.
In the FDA’s dynamic regulatory environment, the patient voice has been adopted and end points for clinical trials have evolved from overall survival to other efficacy measures. “Having multiple drugs is a good thing. Many are approved on nonsurvival end points, and they have transformed the diseases,” said Richard Pazdur, MD.
The NCCN’s first guideline for side effects from immunotherapy recognizes a new spectrum of events in patients who are receiving immune checkpoint inhibitor therapy.
“The wide range of potential immune-related adverse events requires multidisciplinary, collaborative management by providers across the clinical spectrum,” according to Michael A. Postow, MD, and colleagues.

At the 2018 NCCN conference, Sharon H. Giordano, MD, MPH, FASCO, Professor of Medicine, Department of Breast Medical Oncology, M.D. Anderson Cancer Center, Houston, provided an update on the treatment of patients with HER2-positive breast cancer, noting an “explosion of new therapies” in recent years that have had a tremendous impact on survival.

Three cancer centers share their experiences related to the struggle of understanding wide variations in the application of sterile compounding and safe handling of oncology hazardous drugs, and the costs and operating burdens of compliance with and adherence to current pharmacy standards.

New results from the phase 3 QuANTUM-R trial showed that quizartinib, an oral, selective FLT3 inhibitor, significantly extended overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) and the FLT3-ITD mutation.

In April 2017, midostaurin (Rydapt) was approved for the treatment of adults with newly diagnosed FLT3-positive AML in combination with standard intensive induction consolidation chemotherapy.

“Mogamulizumab demonstrated convincing clinical activity, not just in skin but also in clearing malignant T-cells in the blood and lymph nodes. PFS and overall global response outcomes are clearly superior,” said Dr Kim.

“The main rationale from the cytotoxic era is to increase efficacy by combining agents that have different mechanisms and nonoverlapping toxicities. The question is whether we can replace nonspecific cytotoxic agents with a specific, more effective immunotherapeutic,” said Donna Przepiorka, MD, PhD, at ASH 2017.

Page 3 of 20
Results 21 - 30 of 195